Acutaas Chemicals Ltd (ACUTAAS) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management now expects to achieve its 1,000 crore CDMO revenue target in FY27, a year early, and has set a new target of 2,000 crores by FY30.
- Commercial revenue has commenced from the battery chemicals business, with the third product launched and a fourth in validation, signaling a major diversification milestone.
- Full-year capex is guided at INR 3,000 crore, funding a new INR 1,000 crore electronic chemicals project and the second phase of electrolyte additives.
Performance Overview
- Delivered robust performance driven by strong growth in the Advanced Pharmaceutical Intermediates segment, particularly the CDMO business.
- Successfully commenced commercial revenue generation from the battery chemicals business, marking a significant milestone in the specialty chemicals vertical.
- Inaugurated a new state-of-the-art semiconductor chemicals plant in South Korea ahead of schedule, with qualification batches already being submitted to customers.
- Raised future revenue guidance for the CDMO business, now targeting 2,000 crores by FY30, citing strong order flow and new contracts.
- Navigated cost pressures from geopolitical issues by successfully passing them on, while also managing a temporary shipment pause in the BFC business which has since resumed.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.